Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230073 | 0.89 | MGLL (0.53) | MGLLALDH1A1KMT2AHTTNPSR1 | |
| SCHEMBL10395236 | 0.86 | CPS1 (0.55) | HSD11B1MGLLMEN1ALDH1A1KMT2A | |
| SCHEMBL229876 | 0.86 | HSD11B1 (0.65) | HSD11B1MGLLMEN1ALDH1A1KMT2A | |
| SCHEMBL4496800 | 0.84 | MGLL (0.51) | MGLL | |
| SCHEMBL606329 | 0.84 | MEN1 (0.47) | MEN1ALDH1A1KMT2ASMN1; SMN2HTT | |
| SCHEMBL606330 | 0.84 | MEN1 (0.47) | MEN1ALDH1A1KMT2ASMN1; SMN2HTT | |
| SCHEMBL6141378 | 0.83 | TSHR (0.57) | MEN1ALDH1A1KMT2ASMN1; SMN2P2RX7 | |
| SCHEMBL5705838 | 0.82 | STS (0.58) | MEN1KMT2ANPSR1 | |
| SCHEMBL23215765 | 0.81 | HSP90AA1 (0.55) | HSD11B1MGLL | |
| SCHEMBL29745285 | 0.81 | HSP90AA1 (0.55) | HSD11B1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4408053-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-10-04 | — | — | US | claimed |
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HOFFMAN-LA ROCHE INC. | 2014-11-27 | — | — | US | disclosed |
| US-8829029-B2 | Dual modulators of 5HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2183245-B1 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-07-09 | — | — | EP | disclosed |
| US-20130165432-A1 | Dual Modulators of 5HT2A and D3 Receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8415350-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120040972-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2183245-A2 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-4775761-A | TREATING PSYCHOSES, DEPRESSION, CONVULSIONS AND HYPERTENSION | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-10-04 | — | — | US | disclosed |
| US-4758668-A | 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-07-19 | — | — | US | disclosed |
| US-4710573-A | PSYCHOLOGICAL DISORDERS | HOECHST ROUSSEL PHARMACEUTICALS, INC. (US) | 1987-12-01 | — | — | US | disclosed |
| US-4670447-A | ANALGESICS, ANTIDEPRESSANTS, ANTICONVULSANTS AND HYPOTENSIVE AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-06-02 | — | — | US | disclosed |
| US-4528376-A | 3-(4-Piperidyl)-1,2-benzisoxazoles | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1985-07-09 | — | — | US | disclosed |
| US-4469869-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1984-09-04 | — | — | US | disclosed |
| US-4408053-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-10-04 | — | — | US | disclosed |
| US-4408054-A | ANALGESTICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-10-04 | — | — | US | disclosed |
| EP-0080104-A2 | 3-(4-Piperidyl)-1,2-benzisoxazoles, process for the preparation thereof, and a pharmaceutical composition comprising the same | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-06-01 | — | — | EP | disclosed |
| US-4355037-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS (US) | 1982-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165432-A1 | Dual Modulators of 5HT2A and D3 Receptors | HTR2A, HTR3A, HTR1A | HSD11B1 1368/4885MGLL 4368/4885MEN1 3327/4885 |
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR2C | HSD11B1 4592/4885MGLL 4338/4885MEN1 3878/4885 |
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HTR2A, HTR3A, HTR1A | HSD11B1 1368/4885MGLL 4368/4885MEN1 3327/4885 |
| US-20120040972-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR1A | HSD11B1 1368/4885MGLL 4368/4885MEN1 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.